Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

18 F-DCFPyL-PET/CT in Detecting PSMA Expression in Patients with Metastatic Triple Negative Breast Cancer

Trial Status: active

This phase II trial tests how well 18F-DCFPyL positron emission tomography (PET)/computed tomography (CT) scan works in detecting a specific molecule called prostate-specific antigen (PSMA) in patients with triple negative breast cancer (TNBC) that has spread from where it first started (primary site) to other places in the body (metastatic). PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research,18F-DCFPyL. Because some cancers take up 18F-DCFPyL it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient’s body. 18 F-DCFPyL-PET/CT may be effective in detecting PSMA expression (level) in patients with metastatic TNBC.

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.